Oppenheimer Lowers Teladoc Health (NYSE:TDOC) Price Target to $21.00

Teladoc Health (NYSE:TDOC) had its target price reduced by Oppenheimer from $26.00 to $21.00 in a research report released on Friday morning, Benzinga reports. They currently have an outperform rating on the health services provider’s stock.

A number of other equities analysts have also weighed in on the stock. Royal Bank of Canada cut their price objective on shares of Teladoc Health from $25.00 to $18.00 and set an outperform rating for the company in a research report on Friday. SVB Leerink started coverage on Teladoc Health in a research note on Monday, February 26th. They issued a market perform rating and a $17.00 target price for the company. Canaccord Genuity Group decreased their price target on Teladoc Health from $28.00 to $25.00 and set a buy rating on the stock in a research note on Friday. Citigroup lowered their price target on Teladoc Health from $21.00 to $19.00 and set a neutral rating for the company in a report on Wednesday, February 21st. Finally, Needham & Company LLC reiterated a hold rating on shares of Teladoc Health in a report on Friday. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Hold and a consensus target price of $18.73.

Teladoc Health Price Performance

Shares of NYSE:TDOC opened at $13.40 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.47 and a current ratio of 3.54. The business’s fifty day moving average price is $14.69 and its two-hundred day moving average price is $17.67. The stock has a market cap of $2.27 billion, a PE ratio of -9.50 and a beta of 0.94. Teladoc Health has a one year low of $12.65 and a one year high of $30.41.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Thursday, April 25th. The health services provider reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). Teladoc Health had a negative net margin of 8.90% and a negative return on equity of 10.11%. The company had revenue of $646.13 million for the quarter, compared to analyst estimates of $637.31 million. During the same period in the previous year, the business earned ($0.37) EPS. The firm’s revenue was up 2.7% on a year-over-year basis. On average, analysts forecast that Teladoc Health will post -1.06 EPS for the current fiscal year.

Insider Activity at Teladoc Health

In other Teladoc Health news, insider Laizer Kornwasser sold 7,882 shares of the business’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $19.18, for a total transaction of $151,176.76. Following the transaction, the insider now owns 57,223 shares in the company, valued at $1,097,537.14. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Laizer Kornwasser sold 7,882 shares of Teladoc Health stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $19.18, for a total transaction of $151,176.76. Following the sale, the insider now owns 57,223 shares in the company, valued at $1,097,537.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CTO Nikolaos P. Nanis sold 2,866 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.52, for a total transaction of $41,614.32. Following the completion of the transaction, the chief technology officer now owns 69,850 shares of the company’s stock, valued at $1,014,222. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 135,441 shares of company stock worth $2,038,251. 1.63% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Teladoc Health

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in shares of Teladoc Health by 11.8% in the fourth quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider’s stock worth $377,451,000 after buying an additional 1,855,480 shares during the last quarter. ARK Investment Management LLC increased its position in shares of Teladoc Health by 4.5% in the 4th quarter. ARK Investment Management LLC now owns 21,224,565 shares of the health services provider’s stock worth $457,389,000 after purchasing an additional 912,692 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Teladoc Health by 25.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,834,422 shares of the health services provider’s stock worth $82,636,000 after purchasing an additional 767,999 shares during the last quarter. Norges Bank acquired a new position in Teladoc Health in the fourth quarter worth about $9,714,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Teladoc Health by 37.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,549,585 shares of the health services provider’s stock valued at $28,807,000 after buying an additional 418,909 shares in the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.